AI-generated research brief — verify at source
Home-Based Exercise Reduces Cognitive Impairment and Mental Fatigue During Chemotherapy
A multicenter phase III randomized controlled trial found that a structured home-based exercise program significantly reduced cancer-related cognitive impairment and mental fatigue in patients undergoing chemotherapy, with the strongest effects observed in those on 2-week chemotherapy cycles. The findings are supported by a parallel observation that suppressed inflammatory responses were independently associated with greater cognitive impairment, suggesting a plausible biological mechanism.
What Was Studied
This trial investigated whether a prescribed exercise intervention could reduce cancer-related cognitive impairment (CRCI) and mental fatigue in patients actively receiving chemotherapy, and whether changes in systemic inflammatory markers could help explain any observed cognitive benefits. CRCI affects up to 75% of patients during treatment and frequently co-occurs with mental fatigue, yet evidence-based interventions targeting both outcomes simultaneously remain limited.
How It Was Studied
This was a multicenter, phase III randomized controlled trial enrolling adults diagnosed with any cancer type who were about to begin chemotherapy. Participants were randomly assigned either to a 6-week home-based, individually tailored exercise program called Exercise for Cancer Patients (EXCAP) or to usual care. Cognitive impairment was measured using the Functional Assessment of Cancer Therapy–Cognitive Function, and mental fatigue was assessed with the Multidimensional Fatigue Symptom Inventory. Blood samples were collected to quantify inflammatory markers including IL-1β, IL-6, IL-8, IL-10, IFN-γ, and soluble TNF receptor 1 (sTNFR1). Between-group differences were analyzed using analysis of covariance (ANCOVA), and structural equation modeling was used to explore the pathways linking exercise to cognition and inflammation to cognition.
What Was Observed
- Among participants on 2-week chemotherapy cycles, EXCAP participants reported meaningfully less overall cognitive impairment compared to those receiving usual care, a statistically reliable difference (mean difference 7.0 [SE 3.3]; p = .04). They also reported fewer instances of perceived cognitive impairment (mean difference 4.1 [SE 2.1]; p = .05) and less cognitive impairment noted by others around them (mean difference 0.6 [SE 0.2]; p = .02), suggesting the benefits were detectable both subjectively and socially.
- Mental fatigue was significantly reduced in EXCAP participants on 2-week chemotherapy cycles compared to usual care (mean difference −1.6 [SE 0.5]; p < .01). Importantly, a smaller but still statistically significant reduction in mental fatigue was also observed across all EXCAP participants regardless of chemotherapy cycle length (mean difference −0.7 [SE 0.3]; p = .02), indicating that the mental fatigue benefit generalizes more broadly than the cognitive impairment benefit.
- Suppressed inflammatory responses — characterized by blunted activity across both pro- and anti-inflammatory cytokines — were significantly associated with greater cognitive impairment in patients receiving chemotherapy (path coefficient 0.2 [SE 0.1]; p < .01). This finding suggests that immune dysregulation, rather than inflammation alone, may be a key driver of CRCI.
Why This Matters
CRCI is one of the most distressing and functionally disruptive side effects of cancer treatment, yet it remains poorly understood and underaddressed in clinical research. This trial is among the first phase III RCTs to demonstrate that a home-based, scalable exercise intervention can reduce both cognitive impairment and mental fatigue in this population, while also linking inflammatory biology to the cognitive outcomes. The structural equation modeling approach adds mechanistic depth that is rarely seen in exercise oncology trials, advancing the hypothesis that exercise may work in part by restoring healthy immune responsiveness rather than simply suppressing inflammation.
How to Read This Result
The cognitive benefits were statistically significant only within the subgroup receiving 2-week chemotherapy cycles, which raises questions about generalizability to patients on other treatment schedules and warrants cautious interpretation until replication in larger, cycle-stratified analyses.
Limitations
The abstract does not explicitly report study limitations.